Fig. 4
From: HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
Growth curves of NIH-3T3 cells harboring EGFR WT and mutants treated with or without EGF. NIH-3T3 cells harboring EGFR WT and mutants with the same EGFR expression level were treated with DMEM containing 4% FBS without or with 50 ng/ml EGF (a, b, respectively). Cell viability was determined every day using MTT assay and growth curves plotted as fold increase of cell proliferation compared to day 0, presented as mean ± SEM